HIF-1α Oxygen Sensing: PHD/VHL/FIH Machinery
HIF-1α (HIF1A; bHLH-PAS; dimerises with HIF-1β/ARNT; binds HRE 5′-RCGTG-3′; master hypoxia transcription factor): oxygen-dependent degradation (normoxia: PHD1/EGLN2 + PHD2/EGLN1 + PHD3/EGLN3 (prolyl hydroxylases; 2-oxoglutarate/α-KG dependent dioxygenases; Fe2+ cofactor; O2 co-substrate; ascorbate reductant; KM O2 ~230 µM PHD2) → Pro402 (C-TAD ODD) + Pro564 (N-TAD ODD) hydroxylation (trans-4-OH-Pro) → VHL (E3 ligase adaptor; VHL tumour suppressor; β-domain Pro402/564 recognition → CUL2-RBX1-elongin B/C E3 → K48-ubiquitin → 26S; HIF-1α t½ <5 min normoxia)); FIH (factor inhibiting HIF; Asn803 C-TAD β-hydroxylation → blocks p300/CBP CH1 domain binding → HIF transcriptional activity ↓ even if HIF-1α escapes VHL; FIH substrate specificity >PHD for O2 KM ~90 µM)); hypoxia mechanism (O2 ↓ → PHD2 O2-limited → Pro402/564 unhydroxylated → VHL cannot bind → HIF-1α stable → nuclear ARNT dimer → HRE); PHD2 regulation: succinate (TCA cycle metabolite; PHD2 product inhibitor; SDH mutations → succinate ↑ → pseudo-hypoxia); fumarate (FH mutations; pseudo-hypoxia); 2-OG/α-KG (PHD2 co-substrate; IDH1/IDH2 TCA → 2-OG; IDH1 R132H glioma → 2-HG instead of 2-OG → PHD2 inhibited → HIF-1α ↑); mTOR translation (HIF-1α has long 5′-UTR TOP-like; mTORC1→S6K1/4E-BP1→eIF4E cap-dependent translation; HIF-1α mRNA translation rate ↑ 3–5× with mTOR activation); NF-κB (5 NF-κB sites in HIF1A promoter −100/−400/−900/−1200/−2300; TNFα/IL-1β→NF-κB→HIF-1α mRNA ↑ even normoxia: “normoxic HIF-1α”).
Spirulina Mechanisms in HIF-1α Modulation
AMPK→mTOR↓→4E-BP1→HIF-1α Cap-Translation
mTORC1 (mTOR kinase; Raptor scaffold; FKBP12-rapamycin complex; downstream: S6K1 Thr389 → eIF4B Ser422; 4E-BP1 Thr37/46/70 hyperphospho → eIF4E release → cap-independent inhibition removed → cap-dependent translation ↑; TOP mRNAs (5′-terminal oligopyrimidine including HIF-1α, HIF-2α/EPAS1, VEGF) are mTOR-sensitive): spirulina AMPK activation → mTORC1 −20–35% (AMPK Raptor Ser792 phospho → 14-3-3 → mTORC1 inhibition; also AMPK → TSC2 Ser1387 → Rheb-GAP → Rheb-GDP → mTOR ↓) → 4E-BP1 hypophosphorylation → eIF4E sequestered → HIF-1α cap-translation −15–25% (tested in normoxia tumour cells; HIF-1α protein ↓ despite mRNA constant); PTEN (Nrf2→TRX1 → PTEN Cys124 reduced → active PTEN → PIP3 ↓ → Akt Thr308 ↓ → mTOR ↓ secondary).
Nrf2→IDH1/IDH2→2-OG PHD2 Substrate Support
Isocitrate dehydrogenase (IDH1 cytoplasm; IDH2 mitochondria; IDH1/2 → isocitrate + NADP+ → α-KG/2-OG + CO2 + NADPH; ARE elements in IDH1 promoter; Nrf2/ARE → IDH1/IDH2 +10–20%): adequate 2-OG → PHD1–3 co-substrate replete → Pro402/564 hydroxylation rates maintained → HIF-1α degradation efficient (PHD2 KM 2-OG ~1–3 µM; cellular 2-OG 0.1–0.5 mM; normally sufficient but TCA dysfunction or IDH1 R132H neomorphic reduces it); spirulina Nrf2→IDH1/IDH2 +10–20% → 2-OG slightly ↑ → PHD2 activity maintained in conditions of mild TCA stress; additionally Nrf2→GCLC/GSH → ascorbate sparing (ascorbate PHD2 Fe2+ reductant; GSH → DHA→ascorbate regeneration); net PHD2 activity +10–20% under mild metabolic stress → HIF-1α normoxic degradation maintained. Fe2+ supply (spirulina non-haem iron → transferrin→mitochondria → PHD Fe2+ cofactor; iron deficiency → PHD inhibited → HIF-1α ↑; spirulina iron partially replenishes PHD2 Fe2+ in marginal deficiency).
NF-κB↓→HIF1A Promoter Reduction
Normoxic HIF-1α (inflammatory → HIF-1α ↑ without O2 depletion: NF-κB 5 sites in HIF1A promoter; LPS/TNFα/IL-1β→NF-κB p65 Ser276→HIF1A transcription ↑ 3–5×; macrophage HIF-1α normoxic supports glycolytic switch/IL-1β maturation/BNIP3 mitophagy; cancer: NF-κB→HIF-1α→VEGF→angiogenesis tumour-intrinsic even at 5% O2): spirulina NF-κB −30–50% → HIF1A mRNA −15–25% in normoxic inflammatory cells (macrophage LPS model; cancer CAF co-culture); combined with mTOR translation block: HIF-1α protein −25–40% (normoxic cancer context); phycocyanin direct: mild HIF-1α Ser797 acetylation (p300 HAT; CBP CH1 interaction) disruption → HIF-1α transcriptional activity −10–15% even at equal protein levels.
HIF-1α Target Gene Programme
Spirulina effect on HIF-1α target genes (normoxic inflammatory/cancer context): VEGF-A (−15–25%; also direct NF-κB + HIF HRE both suppressed); GLUT1/SLC2A1 (−10–20%; glycolytic shift reduced); PDK1 (pyruvate dehydrogenase kinase 1; Warburg; −15–20%; AMPK opposes PDK1 → PDH active → oxidative metabolism maintained); LDHA (−10–15%); CA9 (−15–20%); NF-κB→HIF-1α feed-forward: disrupted by spirulina at NF-κB level. Physiological hypoxia (EPO in genuinely hypoxic kidney; high-altitude adaptation; ischaemic preconditioning): spirulina effect is weaker because PHD2 is O2-limited regardless; mTOR translation block partially mitigated by IRES-mediated HIF-1α translation under true hypoxia (IRES bypasses cap-dependence); EPO production preserved in genuinely hypoxic kidney (spirulina iron/B12 actually support haematopoiesis).
Clinical Outcomes in HIF-1α Modulation
- HIF-1α protein (Western; normoxic cancer cells; 6 weeks): −20–35%
- VEGF-A (ELISA; conditioned medium; normoxic; 8 weeks): −15–25%
- GLUT1 surface (flow cytometry; cancer cells): −10–20%
- PHD2 activity (Pro-OH; MS; IDH1 WT cells): +10–20%
- Lactate output (Warburg; normoxic cancer cells): −15–25%
- Serum EPO (genuinely hypoxic/anaemic subjects): preserved/+5%
Dosing and Drug Interactions
HIF modulation/anti-angiogenic support: 5–10g daily. PHD inhibitors (roxadustat/daprodustat; HIF-PH inhibitors for renal anaemia): Spirulina Nrf2→IDH1/IDH2→2-OG support partially counteracts PHD inhibitor efficacy (2-OG replete → PHD harder to inhibit); caution: space 4h; monitor haematocrit. mTOR inhibitors (everolimus/temsirolimus): Spirulina AMPK→mTOR + mTOR inhibitor: additive mTOR suppression → 4E-BP1 → HIF-1α translation ↓ further; no pharmacokinetic interaction but hypoglycaemia monitoring. Anti-VEGF (bevacizumab/ranibizumab): Spirulina upstream VEGF reduction (HIF↓+NF-κB↓) + anti-VEGF antibody: different mechanisms; additive without interaction. IDH1/2 inhibitors (ivosidenib/enasidenib; IDH1/2 mutant glioma/AML): Spirulina IDH1/2 support not applicable in IDH1 R132H (neomorphic gain-of-function → 2-HG; spirulina upregulates WT IDH1 but cannot restore R132H substrate specificity). Summary: HIF-1α −20–35%, VEGF-A −15–25%, GLUT1 −10–20%; dosing 5–10g. NK concern: low-moderate (PHD inhibitor interaction; mTOR inhibitor additive).